MONEY

UCB Announces a Head-to-Head Study Evaluating BIMZELX ® (bimekizumab) versus SKYRIZI ® (risankizumab) in Active Psoriatic Arthritis

Tomas Kauer - ModeratorTomas Kauer - Moderator
Oct 1, 2024 - 00:00
UCB Announces a Head-to-Head Study Evaluating BIMZELX ® (bimekizumab) versus SKYRIZI ® (risankizumab) in Active Psoriatic Arthritis
Read More

Tags:

Previous Article

Perimeter Medical Imaging AI Announces Closing of Non-Brokered Private Placement

Next Article

China stocks surge on stimulus optimism, world stocks off record highs

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Tomas Kauer - Moderator
Tomas Kauer - Moderator

Related Posts

Column-Fed sees higher 'terminal' rate, reached sooner: McGeever

Column-Fed sees higher 'terminal' rate, reached sooner:...

Tomas Kauer - Mode... Sep 19, 2024

Austria's rightward shift puts immigration in crosshairs

Austria's rightward shift puts immigration in crosshairs

Tomas Kauer - Mode... Sep 30, 2024

Huawei's $2,800 phone launch disappoints amid supply concerns

Huawei's $2,800 phone launch disappoints amid supply co...

Tomas Kauer - Mode... Sep 20, 2024